skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Recombinant Fowlpox GM-CSF Vaccine Adjuvant (Code C2686)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Recombinant Fowlpox GM-CSF Vaccine Adjuvant

Definition: A cancer vaccine adjuvant consisting of a recombinant fowlpox virus encoding human granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF binds to specific cell surface receptors on various immuno-hematopoietic cell types, enhancing their proliferation and differentiation and stimulating macrophage and dendritic cell functions in antigen presentation and antitumor cell-mediated immunity. Administration of recombinant fowlpox GM-CSF vaccine adjuvant may induce an immune response against tumor cells. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells.

Display Name: Recombinant Fowlpox GM-CSF Vaccine Adjuvant

Label: Recombinant Fowlpox GM-CSF Vaccine Adjuvant

NCI Thesaurus Code: C2686 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1134686  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Recombinant Fowlpox GM-CSF Vaccine Adjuvant

External Source Codes: 
NSC Code 707299 (see NCI DTP info)
PDQ Closed Trial Search ID 38680
PDQ Open Trial Search ID 38680 (check for NCI PDQ open clinical trial info)
UMLS CUI C1134686

Other Properties:
     Name Value (qualifiers indented underneath)
code C2686
Contributing_Source CTRP
Legacy_Concept_Name Fowlpox-Sargramostim
Semantic_Type Pharmacologic Substance
Semantic_Type Virus

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom